Li et al. demonstrated in a mouse tumor model that the demethylating drug desmethylated cytarabine remodeled Tpex cells, driving differentiation into a more toxic-killing Teff cell subpopulation, and when combined with the single-use anti-PD-1 treatment, significantly increased therapeutic efficacy[223]. Here, PDCD1 is linked to neoplasm.